FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. A...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2023-03, Vol.29 (5), p.838-842
Main Authors: Patel, Timil H, Marcus, Leigh, Horiba, M Naomi, Donoghue, Martha, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Schuck, Robert N, Li, Yangbing, Zhang, Xinyuan, Fourie Zirkelbach, Jeanne, Charlab, Rosane, Liu, Jiang, Yang, Yuching, Lemery, Steven J, Pazdur, Richard, Theoret, Marc R, Fashoyin-Aje, Lola A
Format: Article
Language:English
Subjects:
Adult
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - genetics
Bile Ducts, Intrahepatic - pathology
Cholangiocarcinoma - drug therapy
Cholangiocarcinoma - genetics
Cholangiocarcinoma - pathology
Drug Approval
Humans
Hyperphosphatemia
Receptor, Fibroblast Growth Factor, Type 2 - genetics
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Approval was based on FIGHT-202 (NCT02924376), a multicenter open-label single-arm trial. Efficacy was based on 107 patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least one prior therapy and had an FGFR2 gene fusion or rearrangement. Patients received pemigatinib, 13.5 mg orally, once daily for 14 consecutive days, followed by 7 days off therapy. Safety was based on a total of 466 patients, 146 of whom had cholangiocarcinoma and received the recommended dose. Efficacy endpoints were overall response rate (ORR) and duration of response (DOR) determined by an independent review committee using RECIST 1.1. ORR was 36% (95% confidence interval: 27-45). Median DOR was 9.1 months. The most common adverse reactions were hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin. Ocular toxicity and hyperphosphatemia are important risks of pemigatinib. The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy in 21-day cycles. FDA also approved the FoundationOne CDX (Foundation Medicine, Inc.) as a companion diagnostic for patient selection.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-22-2036